ArticleTranslational lung cancer research2026
Treatment patterns and outcomes of later-line therapy in advanced non-small cell lung cancer with unknown or no actionable genomic alterations: a multicenter real-world study in China (RECAP study).
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although first-line immunotherapy has expanded treatment options for advanced non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA), real-world patterns and outcomes of later-line therapies remain poorly defined. This study aimed to characterize these later-line treatment patterns and evaluate their clinical outcomes. Methods: The RECAP study retrospectively analyzed 383 Chinese patients with advanced NSCLC who had unknown or no AGAs and received second-line (2L; n=302) or third-line (3L; n=81) therapy. Treatment regimens were classified as anti-angiogenic (A), chemotherapy (C), chemotherapy-based combinations (C+), immunotherapy (I), immunotherapy-based combinations (I+), and other regimens (O). Results: Treatment patterns, real-world progression-free survival (rwPFS), time to treatment discontinuation (TTD), time to next treatment or death (TTNT), and adverse events (AEs) were collected. In the 2L-enrolled group, the most common regimen was I + C (30.5%), while A + C (21.0%) predominated in the 3L-enrolled group. In the 2L-enrolled group, I + C regimen remained common across treatment lines, while the use of the A regimen increased in the 3L. Median rwPFS was 7.0 months [95% confidence interval (CI): 5.9-9.6] for 2L therapy in the 2L-enrolled group and 7.2 months (95% CI: 5.0-12.8) for 3L therapy in the 3L-enrolled group. I + A achieved the longest rwPFS for 2L therapy in the 2L-enrolled group (13.7 months), and I + A + C for 3L in the 3L-enrolled group (13.6 months). AEs occurred in 13.1% of patients. Conclusions: The RECAP study underscores the prominent role of I+ regimens in later-line settings, with I + C commonly used across treatment lines. These I+ regimens demonstrated favorable clinical outcomes in both 2L and 3L enrolled patients. However, these findings should be interpreted with caution because of the retrospective design, treatment heterogeneity, and exploratory nature of the analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.